Earnings History Data for Aura Biosciences (AURA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Aura Biosciences

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	AH		AURA	Aura Biosciences	540.00	-0.42	-0.44	0.00		10.32	-0.33 (-3.10%)	10.85	0.20 (1.88%)	6.63 - 12.38	81,090	170,000	28,146
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights [2024-11-12 04:05PM]
08-08-2024	PM		AURA	Aura Biosciences	437.00	-0.41	-0.45	0.00	Aura Biosciences GAAP EPS of -$0.41 [8/8/2024 8:05 AM]	8.43	0.24 (2.93%)	0.0	0.0 (0.00%)	5.99 - 12.35	107,084	300,000	0
Aura Biosciences GAAP EPS of -$0.41 [8/8/2024 8:05 AM]
09-11-2023	PM		AURA	Aura Biosciences, Inc.	283.42	-0.48	-0.54	-0.53	Aura Biosciences GAAP EPS of -$0.48 [11/10/2023 7:44 AM]	7.73	0.71 (10.11%)	7.55	0.53 (7.55%)	5.99 - 14.38	286,422	540,000	4,648
Aura Biosciences GAAP EPS of -$0.48 [11/10/2023 7:44 AM] Aura Biosciences director David Johnson buys common shares worth ~$1.44M [11/10/2023 10:35 AM]
09-08-2023	PM		AURA	Aura Biosciences	430.00	-0.48	-0.49	0.00	Aura Biosciences GAAP EPS of -$0.48 [8/9/2023 12:36 PM]	10.98	-0.81 (-6.87%)	0.0	0.0 (0.00%)	8.13 - 24.83	60,290	50,000	0
Aura Biosciences GAAP EPS of -$0.48 [8/9/2023 12:36 PM]
15-03-2023	AH	After the close (Mar 15)	AURA	Aura Biosciences	305.00	-0.52	-0.58	0.00	Aura Biosciences GAAP EPS of -$1.96 misses by $0.02 [3/15/2023 5:12 PM]	10.20	0.02 (0.20%)	10.18	0.0 (0.00%)	9.43 - 24.83	143,983	100,000	4,168
Aura Biosciences GAAP EPS of -$1.96 misses by $0.02 [3/15/2023 5:12 PM]
10-11-2022	PM	Before the open (Nov 10)	AURA	Aura Biosciences	357.00	-0.53	-0.52	0.00	Aura Biosciences GAAP EPS of -$0.54 misses by $0.03 [11/10/2022 9:41 AM]	11.86	0.18 (1.54%)	11.94	0.26 (2.23%)	11.37 - 26.16	741,480	50,000	332
Aura Biosciences GAAP EPS of -$0.54 misses by $0.03 [11/10/2022 9:41 AM] Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights [Nov-10-22 07:00AM] Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma [Nov-10-22 06:45AM]
12-05-2022	AH	4:05 PM ET (May 12)	AURA	Aura Biosciences	487.00	-0.44	-0.44	0.00	Aura Biosciences GAAP EPS of -$0.44 misses by $0.01 [5/12/2022 5:06 PM]	16.61	0.98 (6.24%)	0.0	0.0 (0.00%)	13.50 - 26.16	52,634	50,000	0
Aura Biosciences GAAP EPS of -$0.44 misses by $0.01 [5/12/2022 5:06 PM] Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights [May-12-22 04:15PM]